# EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION

> **NIH NIH N01** · NORTHWESTERN UNIVERSITY · 2020 · $600,700

## Abstract

Epidemiologic studies and randomized trials have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin is associated with a reduced risk of colorectal cancer and adenoma recurrence.  However, long-term use of either enteric-coated or buffered aspirin at low doses of from 75 to 325 mg has been linked to an increased risk of upper and lower gastrointestinal complications (i.e. duodenal and gastric ulcers and gastrointestinal bleeding).

## Key facts

- **NIH application ID:** 10074464
- **Project number:** 261201200035I-P00003-26100009-1
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** SEEMA KHAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $600,700
- **Award type:** —
- **Project period:** 2016-09-01 → 2021-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10074464

## Citation

> US National Institutes of Health, RePORTER application 10074464, EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION (261201200035I-P00003-26100009-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10074464. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*